DAY 1

DAY 2

Speakers 2022

PROGRAM

2 DAYS OF HIGH LEVEL CONFERENCES

The Innovative Therapies Days will make the connection between the academic and the industrial worlds: from research, to clinical trials, to industrialisation.

CAR-T CELLS, CELL THERAPIES, CELL-DERIVED INNOVATIVE THERAPIES

This session will cover a wide range of topics from cell therapies, like CAR-T cells, to new cell-derived therapies. We will develop the understanding mechanisms and research in this session, including the clinic with feedback from international speakers (Austria, China, Germany, …). Transfers in clinical development will also be discussed.

Mixing and exchanges of people from different backgrounds (academics, scientists, pharmacists, clinicians, mature and young biotech companies…) will provide an excellent platform to help the development of cell and gene therapies in France and worldwide to propose these innovative drugs to patients.

REGULATION, PRODUCTION AND CLINICAL TRANSFER OF INNOVATIVE THERAPIES

This session will highlight the capacity of the University Hospital Center to conduct clinical trials and what issues to anticipate. On this occasion, we will give examples from the regional ecosystem with pre-industrial structures.

We will also talk about the regulatory science and innovation task force by the European Medicines Agency and the guidelines defined for ATMPs in European and America.

WEDNESDAY, OCTOBER 11TH

17 :00 – 21 :00 : Visit of Bio Innovation and friendly welcome reception

Presentation of the regional eco-system

Thursday, October 12th

8:30-09:00 : REGISTRATION AND WELCOME COFFEE (KURSAAL BALLROOM)

9:00-09:25 : WELCOME ADRESS AND INTRODUCTION (KURSAAL CONF ROOM)

Introductive words, Sylvain Perruche, RIGHT Institute, Besançon, FR

Welcome words from the urban community’s President and the Region’s President

 

 

9:25-12:30 : CAR-T CELLS (KURSAAL CONF ROOM)

Chairmen : Dr Christophe Ferrand and Dr Marina Deschamps, RIGHT institute, Besançon, FR

 

09:25 : High Effectiveness and Safety of Anti-CD7 CAR T-Cell Therapy in Treating Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Peihua (Peggy) Lu, MD, Lu Daopei Hospital and Beijing Lu Daopei Institute of Hematology, China

 

09:55 : Enabling manufacturing of gene-editing cell therapies

Dr Mélanie Rietenbach, Miltenyi Biotech, Düsseldorf, Germany

 

10:25 : Small talk

xx, xx, xx

 

10:30 : BREAK – EXHIBITION HALL

 

11:00 : UPCOMING TITLE

xx, xx, xx

 

11:30 : Allogeneic CAR T-cells for Adoptive Cell Therapy

Dr Roman Galetto, Cellectis, Paris, France

 

12:00 : Identification of molecular mechanisms governing CAR-T cell response using single cell transcriptomics

Dr Juan R. Rodriguez-Madoz, Center for Applied Medical Research (CIMA), University of Navarra, Spain

12:30 : Small talk

xx, xx

12:35-14:00 : LUNCH (KURSAAL BALLROOM)

 

13:30-15:00 : Exhibition Hall – B2B MEETINGS

 Is a matchmaking session

14:15-15:00 : SYMPOSIUM  – INSTITUT RIGHT (KURSAAL CONF ROOM)

 

15:00-18:30 : UPCOMING INNOVATIVE THERAPIES (KURSAAL CONF ROOM)

Chairmen :XX, xx and Dr Sylvain Perruche, RIGHT Institute, Besançon, FR

 

15:00 : UPCOMING TITLE

Philippe Gruet, Vetoquinol, Lure, France

 

15:30 : Upcoming Title

XX, xx

 

16:00 :  SECRETOME FROM PERIPHERAL WHITE BLOOD CELLS (PBMCS) DRIVEN INTO APOPTOSIS FOR TISSUE REPAIR – TITLE TO BE ANNOUNCED

Prof. Dr. Hendrik Ankersmit, Medical University of Vienna and Aposcience, Vienne, Austria

 

16:30 : Small talk

 

16:35 : BREAK – EXHIBITION HALL

 

17:00 : UPCOMING TITLE

xx, xx, xx

 

17:30 : CELLS OR SECRETOME FOR TREATMENT OF HEART FAILURE

Prof. Dr. Philippe Menasché, Department of Cardiovascular Surgery and  INSERM U970 – Hôpital Européen Georges Pompidou, Paris, France

18:00-19:00 :  B2B MEETINGS

19:00-20:00 :  COCKTAIL

20:00-23:30 : EVENING RECEPTION (KURSAAL BALLROOM)

 

 

Friday, October 13th

09:00 – 12:00

Regulation, production and clinical transfer of innovative therapies

(KURSAAL CONF ROOM)

Chairmen: XX xx

 

09:00 : Regulatory Science and Innovation Task Force, Title to be announced

Dr Oriane Blanquie, European Medicines Agency, Amsterdam, Netherlands

 

09:30 : UPCOMING TITLE

XX, xx, xx

 

10:00 : BREAK- EXHIBITION HALL

 

10:30 : UPCOMING TITLE

Pr Eric Toussirot, Besançon University Hospital, Besançon, France

 

11:00 : UPCOMING TITLE

xx, xx, xx

 

11:30 : UPCOMING TITLE

Dr Jérémy Magalon, AP-HM, Marseille, France

 

12:00-14:00 : LUNCH (KURSAAL BALLROOM)

 

12:40-14:00 :  Exhibition Hall – B2B MEETINGS

Is a matchmaking session

 

14:00-16:30 : CELL THERAPIES (KURSAAL CONF ROOM)

Chairmen : xx and xx 

 

14:00 : UPCOMING TITLE

xx, xx, xx

 

14:30 :  Human CD34+ cells for the treatment of acute ischemic stroke

Dr. Ibon Garitaonandia, CellProthera, Mulhouse, France

 

15:00 : BREAK- EXHIBITION HALL

 

15:30 :UPCOMING TITLE

xx, xx, xx

 

16:00 : UPCOMING TITLE

xx, xx, xx

 

16:30-CONCLUSION END OF CONGRESS

16:45 – BEER PARTY AND/OR B2B MEETNGS ?

 Is a matchmaking session

 

 

Join us and meet our speakers

Dr Marina DESCHAMPS – Right Institute (Besançon, FR), Dr Christophe FERRAND – Right Institute (Besançon, FR), Dr Mathieu GUERRIAUD – CREDIMI (Dijon, FR),  Sylvain PERRUCHE – RIGHT Institute (Besançon, FR), Dr Peihua (Peggy) LU – Lu Daopei Hospital & Institute of Hematology (Beijing, RPC), Dr Melanie RIETENBACH – Miltenyi Biotec ( Düsseldorf, DE), Dr Oriane BLANQUIE, EMA ( Amsterdam, NL)

Speakers